Trump's drug pricing agreements with major pharma companies signal a fundamental shift in how the U.S. healthcare system operates. Companies that adapt quickly could gain significant competitive advantages.
Firms with strong domestic manufacturing and distribution networks may be better positioned to navigate new pricing pressures whilst maintaining profitability in this evolving landscape.
The move towards most-favoured-nation pricing could create winners and losers across the pharmaceutical sector. Early positioning in adaptive companies could prove rewarding as the industry reshapes itself.
Market capitalisation breakdown for the basket 'Pharma's New Pricing Paradigm'.
LLY: $788.86B
MRK: $214.78B
CVS: $98.80B
The Trump administration's drug pricing agreements with major pharmaceutical companies like AstraZeneca and Pfizer represent a fundamental shift towards most-favoured-nation pricing. This policy change could reshape industry profitability and create new opportunities for companies that can adapt to the evolving healthcare landscape.
This group focuses on pharmaceutical companies with strong domestic manufacturing capabilities and key players in the healthcare supply chain. These firms may be more resilient to pricing pressures or could benefit from new market dynamics as the industry adapts to government-controlled pricing models.
These stocks were handpicked by professional analysts based on their potential to navigate the new pricing paradigm. The selection includes pharmaceutical producers, distributors, and healthcare service providers positioned to adapt to significant policy changes that may reshape the entire sector.
The Trump administration's recent drug pricing agreements with major pharmaceutical companies like AstraZeneca and Pfizer aim to lower U.S. drug costs by tying them to international prices. This creates a potential investment opportunity in pharmaceutical firms with strong domestic production and those in the healthcare supply chain that can adapt to the new pricing landscape.
์ด ๋ฐ์ค์ผ์ ์ ์ฒด ์คํ ๋ฆฌ๋ฅผ ํ์ธํ์ธ์. ๋ฆฌ์คํฌ์ ์ ์ฌ๋ ฅ์ ๋ค๋ฃฌ ์์ธ ๊ธฐ์ฌ๋ฅผ ์ฝ์ด๋ณด์ธ์.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
10์ 12 ๊ฒ์
Gilead Sciences has secured FDA approval for a new once-daily HIV combination pill, streamlining therapy for millions of suppressed patients. This regulatory milestone spotlights investment opportunities in pioneering biopharmaceutical companies and drug delivery developers focused on advanced antiviral treatments.
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
+9
Here are a few of the assets in this group. Create an account to unlock the full list.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
์ด ์์ฐ๋ค์ ํฌ์ํ๋ค๋ฉด:
12๊ฐ์ ํ ์์ ๊ฐ์น:
+17.35%
์ ๋๋ฆฌ์คํธ๋ค์ ์ด ๊ทธ๋ฃน์ ์์ฐ์ด ํฅํ 1๋ ๊ฐ ํ๊ท 17.35% ์ฑ์ฅํ ๊ฒ์ผ๋ก ์์ํฉ๋๋ค.
์ด ๊ทธ๋ฃน์ ์์ฐ 19๊ฐ ์ค 16๊ฐ๊ฐ ์ ๋ฌธ ์ ๋๋ฆฌ์คํธ๋ก๋ถํฐ ๋งค์ ์๊ฒฌ์ ๋ฐ์์ต๋๋ค.
